CST5 and CTSS

Number of citations of the paper that reports this interaction (PubMedID 8083219)
8

Data Source:
BioGRID (pull down)
HPRD (in vitro)

		CST5	CTSS
Description		cystatin D	cathepsin S
Image
GO Annotations	Cellular Component	Extracellular Region Extracellular Space Extracellular Exosome	Extracellular Region Extracellular Space Lysosome Late Endosome Endolysosome Lumen Lysosomal Lumen Intracellular Membrane-bounded Organelle Collagen-containing Extracellular Matrix Tertiary Granule Lumen Ficolin-1-rich Granule Lumen
	Molecular Function	Cysteine-type Endopeptidase Inhibitor Activity Protein Binding	Fibronectin Binding Cysteine-type Endopeptidase Activity Collagen Binding Laminin Binding Proteoglycan Binding
	Biological Process	Negative Regulation Of Endopeptidase Activity	Toll-like Receptor Signaling Pathway Adaptive Immune Response Proteolysis Immune Response Response To Acidic PH Protein Processing Antigen Processing And Presentation Antigen Processing And Presentation Of Exogenous Peptide Antigen Via MHC Class II Extracellular Matrix Disassembly Collagen Catabolic Process Basement Membrane Disassembly Neutrophil Degranulation Antigen Processing And Presentation Of Peptide Antigen Proteolysis Involved In Cellular Protein Catabolic Process Cellular Response To Thyroid Hormone Stimulus Positive Regulation Of Cation Channel Activity
Pathways			Endosomal/Vacuolar pathway Degradation of the extracellular matrix Degradation of the extracellular matrix Trafficking and processing of endosomal TLR Assembly of collagen fibrils and other multimeric structures MHC class II antigen presentation Neutrophil degranulation
Drugs			Morpholine-4-Carboxylic Acid [1s-(2-Benzyloxy-1r-Cyano-Ethylcarbamoyl)-3-Methyl-Butyl]Amide Morpholine-4-Carboxylic Acid (1-(3-Benzenesulfonyl-1-Phenethylallylcarbamoyl)-3-Methylbutyl)-Amide Morpholine-4-Carboxylic Acid [1-(2-Benzylsulfanyl-1-Formyl-Ethylcarbamoyl)-2-Phenyl-Ethyl]-Amide N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(MORPHOLIN-4-YLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE N-(1-CYANOCYCLOPROPYL)-3-({[(2S)-5-OXOPYRROLIDIN-2-YL]METHYL}SULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-FLUOROPHENYL)ETHYL]-L-ALANINAMIDE N-[1-(AMINOMETHYL)CYCLOPROPYL]-3-(BENZYLSULFONYL)-N~2~-[(1S)-2,2,2-TRIFLUORO-1-(4-HYDROXYPHENYL)ETHYL]-L-ALANINAMIDE N~2~-1,3-BENZOXAZOL-2-YL-3-CYCLOHEXYL-N-{2-[(4-METHOXYPHENYL)AMINO]ETHYL}-L-ALANINAMIDE N-[(1S)-1-{1-[(1R,3E)-1-ACETYLPENT-3-EN-1-YL]-1H-1,2,3-TRIAZOL-4-YL}-1,2-DIMETHYLPROPYL]BENZAMIDE (1R)-2-[(CYANOMETHYL)AMINO]-1-({[2-(DIFLUOROMETHOXY)BENZYL]SULFONYL}METHYL)-2-OXOETHYL MORPHOLINE-4-CARBOXYLATE 2-[(2',3',4'-TRIFLUOROBIPHENYL-2-YL)OXY]ETHANOL N-[(1S)-2-[(4-cyano-1-methylpiperidin-4-yl)amino]-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide N-[(1S)-2-{[(1R)-2-(benzyloxy)-1-cyano-1-methylethyl]amino}-1-(cyclohexylmethyl)-2-oxoethyl]morpholine-4-carboxamide
Diseases
GWAS		Blood protein levels ( 30072576 28240269) Body mass index (change over time) in cancer or chronic obstructive pulmonary disease ( 28044437) Disease progression in age-related macular degeneration (adjusted for baseline) ( 29346644) Response to TNF antagonist treatment ( 18615156)	Blood protein levels ( 30072576 29875488 28240269) Body mass index ( 26426971) Congenital left-sided heart lesions ( 26965164) Fat body mass ( 24064335) Rhegmatogenous retinal detachment ( 23585552)
Interacting Genes		1 interacting genes: CTSS	9 interacting genes: ANXA2 BGLAP CST3 CST5 KNG1 PLCG1 SERPINB3 SERPINB4 SLPI
Entrez ID		1473	1520
HPRD ID		00463	00292
Ensembl ID		ENSG00000170367	ENSG00000163131
Uniprot IDs		P28325	P25774
PDB IDs		1RN7 1ROA	1BXF 1GLO 1MS6 1NPZ 1NQC 2C0Y 2F1G 2FQ9 2FRA 2FRQ 2FT2 2FUD 2FYE 2G6D 2G7Y 2H7J 2HH5 2HHN 2HXZ 2OP3 2R9M 2R9N 2R9O 3IEJ 3N3G 3N4C 3OVX 4P6E 4P6G 5QBU 5QBV 5QBW 5QBX 5QBY 5QBZ 5QC0 5QC1 5QC2 5QC3 5QC4 5QC5 5QC6 5QC7 5QC8 5QC9 5QCA 5QCB 5QCC 5QCD 5QCE 5QCF 5QCG 5QCH 5QCI 5QCJ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?